Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1975 Aug;37(8):795–803. doi: 10.1136/hrt.37.8.795

Quantitation of infarct size in man by means of plasma enzyme levels.

S A Witteveen, H C Hemker, L Hollaar, W T Hermens
PMCID: PMC482877  PMID: 1191441

Abstract

A method is described in which the extent of myocardial infarction in man is assessed by mathematical analysis of the rise in plasma enzyme levels after infarction. Five enzymes are used in this study: lactate dehydrogenase (LDH); alpha-hydroxybutyrate dehydrogenase (alpha-HBDH); aspartate aminotransferase (GOT); creatine phosphokinase (CPK); and phosphohexoseisomerase (PHI). It is shown that a reasonable assessment of the total enzyme release, reflecting the extent of the infarcted area, can be made when a sufficient number of blood samples are taken after infarction. This could provide a method by which to judge therapeutic effects of intervention in the course of a myocardial infarction, as demonstrated in this study by the assessment of the effect of urokinase on the enzyme release after an infarct.

Full text

PDF
795

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bresnahan G. F., Roberts R., Shell W. E., Ross J., Jr, Sobel B. E. Deleterious effects due to hemorrhage after myocardial reperfusion. Am J Cardiol. 1974 Jan;33(1):82–86. doi: 10.1016/0002-9149(74)90742-5. [DOI] [PubMed] [Google Scholar]
  2. Brogden R. N., Speight T. M., Avery G. S. Streptokinase: a review of its clinical pharmacology, mechanism of action and therapeutic uses. Drugs. 1973;5(5):357–445. doi: 10.2165/00003495-197305050-00002. [DOI] [PubMed] [Google Scholar]
  3. Burkart F., Duckert F., Straub P. W., Frick P. G., Schweizer W., Koller F. Die fibrinolytische Therapie beim akuten Myokardinfarkt. Schweiz Med Wochenschr. 1973 Dec 15;103(50):1814–1816. [PubMed] [Google Scholar]
  4. DUNN M., MARTINS J., REISSMANN K. R. The disappearance rate of glutamic oxalacetic transaminase from the circulation and its distribution in the body's fluid compartments and secretions. J Lab Clin Med. 1958 Feb;51(2):259–265. [PubMed] [Google Scholar]
  5. ELLIOTT B. A., WILKINSON J. H. Serum "alpha-hydroxybutyric dehydrogenase" in myocardial infarction and in liver disease. Lancet. 1961 Apr 1;1(7179):698–699. doi: 10.1016/s0140-6736(61)91724-x. [DOI] [PubMed] [Google Scholar]
  6. Ginks W. R., Sybers H. D., Maroko P. R., Covell J. W., Sobel B. E., Ross J., Jr Coronary artery reperfusion. II. Reduction of myocardial infarct size at 1 week after the coronary occlusion. J Clin Invest. 1972 Oct;51(10):2717–2723. doi: 10.1172/JCI107091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Harnarayan C., Bennett M. A., Pentecost B. L., Brewer D. B. Quantitative study of infarcted myocardium in cardiogenic shock. Br Heart J. 1970 Nov;32(6):728–732. doi: 10.1136/hrt.32.6.728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. KONTTINEN A., HALONEN P. I. Serum alpha-hydroxybutyric dehydrogenase (HBD) in myocardial infarction. Comparison with glutamic oxalacetic transminase (GOT) and lactic dehydrogenase (LDH). Am J Cardiol. 1962 Oct;10:525–531. doi: 10.1016/0002-9149(62)90377-6. [DOI] [PubMed] [Google Scholar]
  9. LADUE J. S., WROBLEWSKI F., KARMEN A. Serum glutamic oxaloacetic transaminase activity in human acute transmural myocardial infarction. Science. 1954 Sep 24;120(3117):497–499. doi: 10.1126/science.120.3117.497. [DOI] [PubMed] [Google Scholar]
  10. Maroko P. R., Kjekshus J. K., Sobel B. E., Watanabe T., Covell J. W., Ross J., Jr, Braunwald E. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971 Jan;43(1):67–82. doi: 10.1161/01.cir.43.1.67. [DOI] [PubMed] [Google Scholar]
  11. Mathey D., Biefield W., Hanrath P., Effert S. Attempt to quantitate relation between cardiac function and infarct size in acute myocardial infarction. Br Heart J. 1974 Mar;36(3):271–279. doi: 10.1136/hrt.36.3.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Rosalki S. B. An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med. 1967 Apr;69(4):696–705. [PubMed] [Google Scholar]
  13. Shell W. E., Kjekshus J. K., Sobel B. E. Quantitative assessment of the extent of myocardial infarction in the conscious dog by means of analysis of serial changes in serum creatine phosphokinase activity. J Clin Invest. 1971 Dec;50(12):2614–2625. doi: 10.1172/JCI106762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Shell W. E., Lavelle J. F., Covell J. W., Sobel B. E. Early estimation of myocardial damage in conscious dogs and patients with evolving acute myocardial infarction. J Clin Invest. 1973 Oct;52(10):2579–2590. doi: 10.1172/JCI107450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sybers H. D., Maroko P. R., Ashraf M., Libby P., Braunwald E. The effect of glucose-insulin-potassium on cardiac ultrastructure following acute experimental coronary occlusion. Am J Pathol. 1973 Mar;70(3):401–420. [PMC free article] [PubMed] [Google Scholar]
  16. WROBLEWSKI F. Clinical significance of serum enzyme alterations associated with myocardial infarction. Am Heart J. 1957 Aug;54(2):219–224. doi: 10.1016/0002-8703(57)90149-7. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES